Advertisement
DALLAS, May 22, 2015 /PRNewswire-iReach/ -- The report "Schistosomiasis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects.
(Photo - http://photos.prnewswire.com/prnh/20150522/218052)
Schistosomiasis is a disease caused by parasitic worms. Infection is acquired when people come into contact with fresh water infested with the larval forms of parasitic blood flukes. Schistosomiasis affects almost 240 million people worldwide, and more than 700 million people live in endemic areas. Symptoms vary with the species of worm and the phase of infection.
Companies discussed in this Schistosomiasis – Pipeline Review, H1 2015 report include:
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Reasons to buy
More reports on Infectious Diseases Therapeutics
Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2015
The report "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Sepsis – Pipeline Review, H1 2015
The report "Sepsis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Adrenomed AG, Altor BioScience Corporation, Am-Pharma B.V., Arch Biopartners, Inc., Asahi Kasei Pharma Corp., Baxter International Inc., Biomedica Management Corporation, Chiesi Farmaceutici SpA, Chiome Bioscience, Inc., Cilian AG, Cognosci, Inc., Diomune S.L, Endacea, Inc., Evec, Inc., Huons Co., Ltd., Immune Response BioPharma, Inc., ImmunNovative Developments SL, InflaRx GmbH, Integrated BioTherapeutics, Inc., ISU ABXIS Co.,Ltd., Lead Discovery Center GmbH, MSM Protein Technologies, Inc., Navigen Pharmaceuticals, Inc., Novadiscovery SAS, Noxxon Pharma AG, Ocata Therapeutics, Inc., OncoImmune, Inc., Opsona Therapeutics Ltd., ProThera Biologics, LLC., Silence Therapeutics plc, Stemedica Cell Technologies, Inc., Syntiron LLC, Takeda Pharmaceutical Company Limited, TiGenix NV, XImmune AB.
Measles – Pipeline Review, H1 2015
The report "Measles – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Measles. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include Beijing Tiantan Biological Products Co., Ltd., Biological E. Limited, China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Prometheon Pharma, LLC, Serum Institute of India Limited, Universal Stabilization Technologies, Inc., Vical Incorporated, Zydus Cadila Healthcare Limited.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
Advertisement
(Photo - http://photos.prnewswire.com/prnh/20150522/218052)
Schistosomiasis is a disease caused by parasitic worms. Infection is acquired when people come into contact with fresh water infested with the larval forms of parasitic blood flukes. Schistosomiasis affects almost 240 million people worldwide, and more than 700 million people live in endemic areas. Symptoms vary with the species of worm and the phase of infection.
Companies discussed in this Schistosomiasis – Pipeline Review, H1 2015 report include:
- BioDiem Ltd
- Concert Pharmaceuticals, Inc.
- Kancera AB
- LondonPharma Ltd
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
More reports on Infectious Diseases Therapeutics
Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2015
The report "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Sepsis – Pipeline Review, H1 2015
The report "Sepsis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Adrenomed AG, Altor BioScience Corporation, Am-Pharma B.V., Arch Biopartners, Inc., Asahi Kasei Pharma Corp., Baxter International Inc., Biomedica Management Corporation, Chiesi Farmaceutici SpA, Chiome Bioscience, Inc., Cilian AG, Cognosci, Inc., Diomune S.L, Endacea, Inc., Evec, Inc., Huons Co., Ltd., Immune Response BioPharma, Inc., ImmunNovative Developments SL, InflaRx GmbH, Integrated BioTherapeutics, Inc., ISU ABXIS Co.,Ltd., Lead Discovery Center GmbH, MSM Protein Technologies, Inc., Navigen Pharmaceuticals, Inc., Novadiscovery SAS, Noxxon Pharma AG, Ocata Therapeutics, Inc., OncoImmune, Inc., Opsona Therapeutics Ltd., ProThera Biologics, LLC., Silence Therapeutics plc, Stemedica Cell Technologies, Inc., Syntiron LLC, Takeda Pharmaceutical Company Limited, TiGenix NV, XImmune AB.
Measles – Pipeline Review, H1 2015
The report "Measles – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Measles. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include Beijing Tiantan Biological Products Co., Ltd., Biological E. Limited, China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Prometheon Pharma, LLC, Serum Institute of India Limited, Universal Stabilization Technologies, Inc., Vical Incorporated, Zydus Cadila Healthcare Limited.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
